Aduro BioTech CEO and leadership

Stephen 'Steve' Isaacs is a Board Of Director at X-BIOTIX THERAPEUTICS INC; Board Member at Pan Pacific Pharmaceuticals, Inc.; and Chairman and CEO at ADURO BIOTECH, INC. and is based in Orinda, California. He has worked as Founder, President and CEO at Cerus Corporatioin; Research Staff at University of California Berkeley; and Board Member at Cerus. Stephen works or has worked as MEMBER at ABE Club. He attended University of California Berkeley.

William G. Kachioff joined Aduro in January 2020 as Interim Chief Financial Officer. He is an employee of Danforth Advisors, LLC and has worked as an executive consultant for life sciences companies since September 2017. Mr. Kachioff served as chief financial officer of GenomeDx Biosciences (now known as Decipher Biosciences), a cancer diagnostics company, from November 2015 to May 2017, senior vice president and chief financial officer of Biocept, Inc., a molecular diagnostics company, from 2011 to 2015, and chief financial officer of Althea Technologies, Inc., a pharmaceutical contract manufacturer, from 2009 to 2011. Mr. Kachioff graduated from University at Buffalo, State University of New York with a B.S. in Management with concentrations in Accounting and Management of Information Sciences. He is a member of the American Institute of Certified Public Accountants and the Association of Bioscience Financial Officers.

Highly accomplished senior executive and board director with 20+ years of experience in biotechnology drug development. Outstanding leader with demonstrated excellence in biotech company formation, strategy, team building, business development, project management, fundraising, investor relations and alliance management. Deep subject matter expertise in cancer immunotherapy, immunology, oncology and antibody therapeutics. Significant background achievements include: a Dutch Cancer Society fellowship that allowed for co-discovering the use of anti-CTLA-4 in cancer immunotherapy in the U.C. Berkeley lab of 2018 Nobel laureate, Professor James. P. Allison, as well as the opportunity at Organon / Schering-Plough / Merck to head up the developing immuno-oncology portfolio and lead the team that developed anti-PD-1, which ultimately became known as Keytruda (pembrolizumab). He holds a supervisory board position with DC Prime, prior board observer with Lava Therapeutics (Aug 2020), chairs the SAB for Lava Therapeutics, and SAB member for InteRNA Technologies.Since 2011 he is VP Research of AM-Pharma, a Dutch clinical stage biopharmaceutical company developing a treatment for acute kidney injury (AKI) and sepsis that could be lifesaving.He founded IREYA B.V. in 2011, a consultancy for (bio)pharmaceutical R&D, management, and patent prosecution related advice. Andrea was an Operational Partner for Gilde Healthcare until Aug 2020. He founded BioNovion in 2011 with two former Organon colleagues to develop novel antibodies for immune oncology. Following its acquisition in 2015 he served as CSO of Aduro Biotech, Inc ($ADRO) and directed the Aduro Biotech Europe site in Oss, NL, until June 2020.From 1999 to 2011, he held various positions in R&D at Organon (1999), Schering Plough (2007) and Merck Sharpe & Dohme (2009). In 2008-2010, he led two cross-functional antibody Early Development Teams, most notably developing anti-PD1 (now known as pembrolizumab), and a Proof-of-Concept Team responsible for Schering-Plough's Immune Oncology portfolio.He trained in molecular cell biology and completed his thesis on melanoma antigens and their use in cancer immunotherapy in 1996 (Leiden Univeristy). A Dutch Cancer Society fellowship in 1997-1999 allowed him to work with Prof. James P. Allison at UC Berkeley (CA), where co-discovered the use of anti-CTLA-4 as the first checkpoint inhibitor to treat cancer.

Dimitry S.A. Nuyten, M.D., Ph.D. joined Aduro in May 2019 as Chief Medical Officer. Prior to joining Aduro, Dr. Nuyten served as Vice President and Immuno-Oncology Clinical Development Leader at Pfizer, where he oversaw the clinical strategy for BAVENCIO® (avelumab), a human anti-programmed death ligand-1 (PD-L1) antibody, utomilumab, a human monoclonal antibody (mAb) agonist that selectively binds to 4-1BB, and additional programs that included pivotal and exploratory trials with immuno-oncology combinations. Prior to Pfizer, he served as Group Medical Director and Exploratory Development Team Leader at Bristol-Myers Squibb, where he was responsible for the development of several early phase compounds in oncology. Dr. Nuyten holds an M.D. from the University of Groningen and a Ph.D. from the University of Amsterdam Medical School in The Netherlands and completed his training in radiation oncology at the Netherlands Cancer Institute (NKI). He has authored numerous peer-reviewed publications and is co-inventor on multiple patents.